UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



|ý |  | QUARTERLY REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE          
|- |  | -----------------------------------------------------------------
|  |  | SECURITIES EXCHANGE ACT OF
1934                                  
|  |  |                                                                  
|  |  | For the quarterly period ended March 31, 2014                    
|  |  |                                                                  
|  |  | OR                                                               
|  |  |                                                                  
|o |  | TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE         
|  |  | SECURITIES EXCHANGE ACT OF
1934                                  
|  |  |                                                                  
|  |  | For the transition period from ______________ to
________________

Commission file number:  000-51134



MMRGLOBAL, INC. (Exact name of Registrant as Specified in Its Charter)

|DELAWARE                                                                                                                              |  | 33-0892797                                                                                                 
|------------------------------------------------------------------------------------------------------------------------------------- |  | -----------------------------------------------------------------------------------------------------------
|(State or Other Jurisdiction of 
                                                                      Incorporation or Organization) |  | (I.R.S. Employer 
                                                                      Identification No.)
|                                                                                                                                      |  |                                                                                                            
|4401 WILSHIRE BLVD., SUITE 200
LOS ANGELES, CA                                                                                        |  | 90010                                                                                                      
|(Address of Principal Executive Offices)                                                                                              |  | (Zip Code)                                                                                                 

(310) 476-7002

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

Yes x
         No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for
such shorter period that the registrant was required to submit and post such files).

Yes x
         No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or
a smaller reporting company.  See the definitions of "large accelerated filer," "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer o
                  Accelerated filer  o
      

Non-accelerated filer  o
  (Do not check if a smaller reporting company)                 Smaller reporting company  x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
                           Yes o
         No  x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable
date:  As of May 9, 2014, the issuer had 731,018,771 shares of common stock outstanding.




Explanatory Note

The sole purpose of this amendment on Form 10-Q/A to MMRGlobal, Inc.'s quarterly report on Form 10-Q for the period ended March 31, 2014, as originally filed with the Securities
and Exchange Commission on May 15, 2014 ("the Form 10-Q"), is to furnish a corrected copy of Exhibit 10.1 to the Form 10-Q, reflecting changes to the confidential treatment request by
MMRGlobal of certain items contained therein.

No other changes have been made to the Form 10-Q. This Form 10-Q/A speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent
to the original filing date, and does not modify or update in any way disclosures made in the Form 10-Q.









---



Item 6. Exhibits

|Exhibit
Number |  | Exhibit Description                                                                                                                                                                                                                                                             
|-------------- |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|               |  |                                                                                                                                                                                                                                                                                 
|10.1           |  | *+ Settlement Agreement dated February 28, 2014 by and between MyMedicalRecrods, Inc. and Walgreen Co.  12 pages of Exhibit A to the
Settlement Agreement have been redacted, in addition to other information for which confidential treatment has been requested and is noted.
|               |  |                                                                                                                                                                                                                                                                                 
|31.1           |  | ** Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.                                                                                                                                                        
|               |  |                                                                                                                                                                                                                                                                                 
|31.2           |  | ** Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.                                                                                                                                                        
|               |  |                                                                                                                                                                                                                                                                                 
|32.1           |  | ** Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.                                                                                                                             
|               |  |                                                                                                                                                                                                                                                                                 
|32.2           |  | ** Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.                                                                                                                             
|               |  |                                                                                                                                                                                                                                                                                 
|101.INS        |  | **  XBRL Instance Document                                                                                                                                                                                                                                                      
|               |  |                                                                                                                                                                                                                                                                                 
|101.SCH        |  | ** XBRL Taxonomy Extension Schema Document                                                                                                                                                                                                                                      
|               |  |                                                                                                                                                                                                                                                                                 
|101.CAL        |  | ** XBRL Taxonomy Extension Calculation Linkbase Document                                                                                                                                                                                                                        
|               |  |                                                                                                                                                                                                                                                                                 
|101.DEF        |  | ** XBRL Taxonomy Extension Definition Linkbase Document                                                                                                                                                                                                                         
|               |  |                                                                                                                                                                                                                                                                                 
|101.LAB        |  | ** XBRL Taxonomy Extension Label Linkbase Document                                                                                                                                                                                                                              
|               |  |                                                                                                                                                                                                                                                                                 
|101.PRE        |  | ** XBRL Taxonomy Extension Presentation Linkbase Document                                                                                                                                                                                                                       

______________

|*  | Filed herewith.                                                                                               
|-- | --------------------------------------------------------------------------------------------------------------
|** | Previously filed on May 15, 2014, with the Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
|+  | The Company has requested confidential treatment with respect to portions of this exhibit.                    

---



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.

Date:   August 6, 2014

MMRGlobal, Inc.

By:/s/ Robert H.
Lorsch     Robert H. Lorsch
     Chairman, Chief Executive Officer and
     President

By:/s/ Ingrid G. Safranek     Ingrid G. Safranek
     Chief Financial Officer

---

EXHIBIT INDEX

Exhibit
Number

Exhibit Description10.1

*+ Settlement Agreement dated February 28, 2014 by and between MyMedicalRecrods, Inc. and Walgreen Co.  12 pages of Exhibit A to the
Settlement Agreement have been redacted, in addition to other information for which confidential treatment has been requested and is noted.31.1

** Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.31.2

** Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.32.1

** Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.32.2

** Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350.101.INS

**  XBRL Instance Document101.SCH

** XBRL Taxonomy Extension Schema Document101.CAL

** XBRL Taxonomy Extension Calculation Linkbase Document101.DEF

** XBRL Taxonomy Extension Definition Linkbase Document101.LAB

** XBRL Taxonomy Extension Label Linkbase Document101.PRE

** XBRL Taxonomy Extension Presentation Linkbase Document______________

*
Filed herewith.**
Previously filed on May 15, 2014, with the Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.+
The Company has requested confidential treatment with respect to portions of this exhibit.